LOXO-292 demonstrates promising anti-tumor activity in RET-altered thyroid cancer
ITOG member Dr. Lori Wirth recently presented progress on a Phase 1/2 study of LOXO-292 at the European Society for Medical Oncology (ESMO) Annual Congress in Barcelona, Spain. This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LOXO-292 administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Recent Posts
Catch up on the latest from ITOG—research progress, community updates, and highlights shaping the future of thyroid [...]
2024 Robert F. Gagel ITOG Discovery Award Winner: Jim Fagin, MD for “Leveraging therapeutic vulnerabilities induced by [...]
